

PRESS RELEASE

Stockholm, Sweden, 15 July 2016



Sobi's Board of directors exercises its authorisation for repurchase of shares to secure the company's commitments under the incentive programme

The annual general meeting of [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) on 24 May 2016 resolved – for the purpose of ensuring that the company can fulfill its commitments under the long-term incentive programme resolved by the annual general meeting – on a directed share issue of no more than 188,142 redeemable and convertible class C shares.

The general meeting also resolved to authorise the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the annual general meeting in 2017 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 15 July – 27 September 2016.

The company currently holds 1,640,735 own common shares and 1,433,036 own class C shares. Subsequently to the effected repurchase of class C shares above, the number of own class C shares will amount to 1,621,178.

The class C shares will, following the repurchase, be converted to common shares in the number that is required to ensure delivery under the incentive programme.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations

Oskar Bosson, Head of Communications

+46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

+1 347-224-0819, +1 212-579-0506, +46 8 697 2135

jorgen.winroth@sobi.com

The information was released for public distribution on 15 July 2016 at 08:30 am CET.